Malta - English - Medicines Authority

ferring pharmaceuticals limited - budesonide - prolonged-release tablet - budesonide 9 milligram(s) - antidiarrheals, intestinal antiinflammatory/antiinfective agents

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

European Union - English - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - follitropin delta - anovulation - sex hormones and modulators of the genital system, - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

European Union - English - EMA (European Medicines Agency)

mallinckrodt pharmaceuticals ireland limited - human fibrinogen, human thrombin - hemostasis, surgical - antihemorrhagics - supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis.raplixa must be used in combination with an approved gelatin sponge.raplixa is indicated in adults over 18 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - galsulfase 1 mg/ml - concentrate for infusion - 1 mg/ml - active: galsulfase 1 mg/ml excipient: polysorbate 80 sodium chloride sodium phosphate water for injection - naglazyme is indicated as long term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi, n-acetylgalactosamine 4-sulfatase deficiency, maroteaux-lamy syndrome).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - elosulfase alfa 1 mg/ml;   - concentrate for injection - 1 mg/ml - active: elosulfase alfa 1 mg/ml   excipient: arginine hydrochloride monobasic sodium phosphate monohydrate polysorbate 20 sodium acetate trihydrate sorbitol water for injection - treatment of mucopolysaccharidosis type iva (mps iva; morquio a syndrome) in children and adults of all ages.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - triptorelin acetate, quantity: 100 microgram (equivalent: triptorelin, qty 95.6 microgram/ml) - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium chloride - decapeptyl 100 micrograms/1 ml is indicated for down-regulation and prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (art).,in clinical trials decapeptyl 100 micrograms/1 ml has been used in cycles where urinary and recombinant human follicle stimulating hormone (fsh) as well as human menopausal gonadotrophin (hmg) were used for stimulation.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - vasoactive intestinal peptide (unii: 6j2wvd66kr) (vasoactive intestinal peptide - unii:6j2wvd66kr) - vasoactive intestinal peptide .495 g in .5 g

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - 1. indications  progestin- only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin- only oral contraceptives is 0.5%. however, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. the following table lists the pregnancy rates for users of all major methods of contraception. emergency contraceptive pills treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.9 lactational amenorrhea method lam is a highly effective, temporary method of contraception.10 source: trussell, j, contraceptive efficacy. in: hatcher ra, trussell j, stewart f, cates w, stewart gk, kowal d, guest f, contraceptive technology: seventeenth revised edition. new york ny: irvington publishers, 1998. - among typical couples who initiate use of a method (not necessarily for the first time), the percentage who exp

Malta - English - Medicines Authority

ferring pharmaceuticals limited drayton hall, church road, west drayton ub7 7ps, united kingdom - u - powder and solvent for solution for injection - urofollitropin 75 iu - sex hormones and modulators of the genital system